A biotechnology company developing treatments for diseases caused by abnormal immune responses to viruses. The company is developing IMC-1, a novel treatment that suppresses the activation and replication of HSV-1, a virus believed to be the cause of chronic diseases such as fibromyalgia, irritable bowel disease, and chronic fatigue syndrome, by combining a unique mechanism of action that puts the virus into a dormant or latent state. The company is based in Delaware.